Jazz Pharmaceuticals Public Limited Company filed a Form 8-K with the U.S. Securities and Exchange Commission on November 2, 2026, reporting results of operations and financial condition for the quarter ended September 30, 2026.

Key Highlights

  • Filing date: November 2, 2026, the same date as the earliest event reported.
  • Reporting period: The quarter ended September 30, 2026.
  • Exchange listing: Ordinary shares, nominal value $0.0001 per share, trade under the symbol JAZZ on The Nasdaq Stock Market LLC (NASDAQ:JAZZ).
  • Exhibit furnished: A press release dated November 2, 2026, is furnished as Exhibit 99.1 and contains the detailed financial results.
  • Signing officer: Philip L. Johnson, Executive Vice President and Chief Financial Officer, signed the filing on behalf of the company.
  • Incorporation: The company is incorporated in Ireland, with principal executive offices located at Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland.

Jazz Pharmaceuticals Announces Third-Quarter 2026 Financial Results via Current Report

Jazz Pharmaceuticals Public Limited Company, an Ireland-incorporated pharmaceutical company whose ordinary shares trade on NASDAQ:JAZZ, submitted a current report on November 2, 2026, under Item 2.02, covering results of operations and financial condition. According to the filing, the company issued a press release on that same date announcing financial results for the quarter ended September 30, 2026. The press release was furnished as Exhibit 99.1 to the current report rather than filed as a formal exhibit.

The filing notes that the information contained in Item 2.02 and in the furnished press release "shall not be deemed to be 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended." The company further disclosed that the information shall not be incorporated by reference into any future or prior regulatory filings, regardless of any general incorporation language in those filings.

Executive Vice President and Chief Financial Officer Philip L. Johnson signed the report on November 2, 2026, on behalf of Jazz Pharmaceuticals Public Limited Company. The company's Commission File Number is 001-33500, and its IRS Employer Identification Number is 98-1032470. The registrant confirmed it is not an emerging growth company as defined under the applicable Securities Act and Exchange Act rules.

What Was Disclosed

Jazz Pharmaceuticals Public Limited Company filed a current report on November 2, 2026, disclosing that it issued a press release announcing financial results for the quarter ended September 30, 2026. The press release is furnished as Exhibit 99.1 and is not deemed formally filed for Exchange Act liability purposes.